Page 1
Page 1
New Vision of Multiblesclerosis
"There is an evidence that both the multiple sclerosis increased prevalence and incidence rate of over the last few decades. Therefore, the goal of our study is to highlight the causes and the risk factors of such neurological disease in order to raise the public awareness for its early symptoms to be able to treat the patients as early as possible and to have the best outcome. The symptoms of this disease are similar to some extent to other diseases so we will design a table and a test for differential diagnosis with such diseases because there is not a specific diagnostic test also taking into consideration to include in our current project A new promising medication (Radicava)which was first approved by FDA in 2015 in Japan 20 years after all old mentioned medications in this study and we started communication with a brilliant neurological doctor to plan using it first time ever in our country. Beside that we will recommend some important diet to follow for patients and some advises to avoid some risk factors which can develop this disease."
Multiple Sclerosis: Autoimmunity and Management
Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system, destroying the myelin and the axon in variable degrees and producing significant physical disability within 20–25 years in more than 30% of patients. The hallmark of MS is symptomatic episodes that occur months or years apart and affect different anatomic locations. Also, see the Autoimmune Disorders: Making Sense of Nonspecific Symptoms slideshow to help identify several diseases that can cause a variety of nonspecific symptoms. MS is diagnosed on the basis of clinical findings and supporting evidence from ancillary tests. Treatment consists of immunomodulatory therapy for the underlying immune disorder and management of symptoms, as well as nonpharmacologic treatments, such as physical and occupational therapy. Disease-modifying therapies have shown beneficial effects in patients with relapsing MS, including reduced frequency and severity of clinical attacks. These agents appear to slow the progression of disability and the reduce accumulation of lesions within the brain and spinal cord.
